Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Forte R, Cennamo GL, Finelli M, Farese E, D′Amico G, Nicoletti G et al. Intravitreal bevacizumab vs intravitreal triamcinolone combined with macular laser grid for diffuse diabetic macular oedema. Eye 2010; 24 (8): 1325–1330.
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ . Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114 (5): 855–859.
Parravano M, Menchini F, Virgili G . Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2009; 7 (4): CD007419.
Gillies MC . What we don’t know about avastin might hurt us. Arch Ophthalmol 2006; 124 (10): 1478–1479.
Steijns D, Duijvesz D, Breedijk MA, van der Heijden GJ . Steroid injection in addition to macular laser grid photocoagulation in diabetic macular oedema: a systematic review. Acta Ophthalmol 2010; 88 (4): 389–393.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no conflict of interest.
Rights and permissions
About this article
Cite this article
Chhablani, J. Anti-VEGF (vascular endothelial growth factor) drugs in diabetic macular oedema. Eye 25, 254 (2011). https://doi.org/10.1038/eye.2010.182
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2010.182
This article is cited by
-
Reply to Chhablani
Eye (2011)
